Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-04-26
2005-04-26
Huff, Sheela J. (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C435S344000, C530S388150, C530S388800
Reexamination Certificate
active
06884418
ABSTRACT:
This invention is directed toward novel synergistic combinations of ligand-mimicking agents specific to the c-erbB-2 protein and anti-neoplastic drugs or agents, which can be used to treat a mammalian host, usually a human, suspected of having cancer or tumor cells by administering the combination in a therapeutically- or synergistically-effective amount. The drug combinations cytotoxic to tumor cells comprise an anti-neoplastic agent and a molecule, that is not conjugated to the anti-neoplastic agent, that binds the tumor cells and induces an increase in the phosphorylation of c-erbB-2 protein when placed in contact with the tumor cells. Alternatively, the drug combination cytotoxic to tumor cells may comprise an anti-neoplastic agent and a molecule, that is not conjugated to the anti-neoplastic agent, that binds the tumor cells and causes down modulation or internalization of c-erbB-2 protein. The anti-neoplastic drug is preferably an alkylating agent, most preferably cisplatin. This combination is particularly effective for inhibiting the growth of breast and ovarian tumor cells. Methods for killing target tumor cells are contemplated by contacting the target cells with the novel drug combinations, methods for treating mammals by administering therapeutic amounts of the drug combinations are also contemplated.
REFERENCES:
patent: 4017471 (1977-04-01), Davies
patent: 4093607 (1978-06-01), Sela et al.
patent: 4140707 (1979-02-01), Cleare et al.
patent: 4172124 (1979-10-01), Koprowski et al.
patent: 4177263 (1979-12-01), Rosenberg et al.
patent: 4699877 (1987-10-01), Cline et al.
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4935341 (1990-06-01), Bargmann et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 0 359 282 (1989-09-01), None
patent: 62-108157 (1985-11-01), None
patent: WO8910412 (1988-04-01), None
patent: WO8906692 (1989-01-01), None
patent: WO8910412 (1989-04-01), None
patent: WO 8906692 (1989-07-01), None
patent: WO8910412 (1989-11-01), None
Harris et al. TibTeln Vol 11. p. 42 1993.*
Osband Immunology Today 11(5) 1990 p. 193.*
Cancer Res. Read et al. 1990, 50(13) 39 47-51 (abstract).*
“Immunotherapy and Monoclonal Ab.” p. 183-187Genes&Cancer1990 Wiley & Sons.*
Identification of a Phosphoprotein Specifically Induced by the Transforming DNA of Rat Neuroblastomas, Lakshmi Charan Padhy et al., Cell, vol. 20, pp. 865-871, Apr. 1982.
Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene, Jeffrey A. Drebin et al., Nature, Vol, 312, pp. 545-548, Dec. 6, 1984.
The neu oncogene: an erb-B-related gene encoding a 185,000-M tumour antigen, Alan L. Schecter et al., Nature, vol. 312, pp. 513-516, Dec. 6, 1984.
The Product of the Human c-erbB-2 Gene: A 185-Kilodalton Glycoprotein with Tyrosine Kinase Activity, Tetsu Aklyama et al., Science, vol. 232, pp. 1644-1646, 1986.
Expression of the c-erbB-2 Protein in Normal and Transformed Cells, William J. Gullick et al., Int. J. Cancer: 40, pp. 246-254, 1987.
Abstract JP 2150293-A2.
U.S. Appl. No. 06/836,414, King et al., filed Mar. 5, 1986.
U.S. Appl. No. 07/389,920, Stuart et al., filed Aug. 4, 1989.
Hudziak R. et al., “p185HER2Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor”,Mol. Cell. Biol., 9:1165-1172 (1989).
Lidor, Y. et al., “Alkylating Agents and Immunotoxins Exert Synergistic Antitumor Activity Against Ovarian Cancer Cell Lines”,Proceedings of the American Association for Cancer Research, 30:401 (1989).
Hurwitz, E. et al., “A Synergistic Effects Between Anti-Idiotype Antibodies and Anti-Neoplastic Drugs in the Therapy of a Murine B-Cell Tumor”,Oncogene, 2:387-394 (1988).
Drebin, J.A. et al., “Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo”,Oncogene, 2:387-394 (1988).
Langton, B. et al., “The development and characterization of antibodies to different regions of the c-erbB-2 protein on breast tumor tissue and cell lines” (Abstract and Poster) American Association for Cancer Research Conference held May 24-27, 1989.
Slamon, D.J. et al., “Studies of the HER-2
eu Proto-oncogene in Human Breast and Ovarian Cancer”,Science, 244:707-712 (1989).
Slamon, D.J. et al., “Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2
eu Oncogene”,Science, 235:177-182 (1987).
Yarden, Y. et al., “Experimental approaches to hypothetical hormones: Detection of a candidate ligand of the neu protooncogene”,Proc. Natl. Acad. Sci. USA, 86:3179-3183 (1989).
King, C.R. et al., “Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma”,Science, 229-974-976 (1985).
Schechter, A.L. et al, “The neu Gene: An erbB-Homologous Gene Distinct from and Unlinked to the Gene Encoding the EGF Receptor”,Science, 229:976-978 (1985).
Semba, K. et al., “A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma”,Proc. Natl. Acad. Sci. USA, 82:6497-6501 (1985).
Coussens, L. et al., “Tyrosine Kinase Receptor with Extensive Homology to EFG Receptor Shares Chromosomal Location with neu Oncogene”,Science, 230:1132-1139 (1985).
Drebin, J.A. et al., “Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies”,Cell, 41:695-706 (1985).
Lupu, R. et al., “Direct Interaction of a Ligand for the erbB2 Oncogene Product with the EGF Receptor and p185erbB2”, Science, 249:1552-1555 (1990).
Kraus, M.H. et al., “Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms”,The EMBO Journal, 6:605-610 (1987).
Connelly, P.A. et al., “The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade”,Proc. Natl. Acad. Sci. USA, 87:6054-6057 (1990).
Hudziak, R.M. et al., “Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor α in NIH 3T3 cells”,Proc. Natl. Acad. Sci. USA, 85:5102-5106 (1988).
Williams, D.E. et al., “Identification of a Ligand for the c-kit Proto-Oncogene”,Cell, 63:167-174 (1990).
Nocka, K. et al., “Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors”,The EMBO Journal, 9:3287-3294 (1990).
Yarden, Y. et al., “Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand”,The EMBO Journal, 6:3341-3351 (1987).
Scanlon, K.J. et al., “Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells”,Proc. Natl. Acad. Sci. USA, 83:8923-8925 (1986).
Scanlon, K.J. et al., “Molecular Basis of Cisplatin Resistance in Human Carcinomas: Model Systems and Patients”,Anticancer Research, 9:1301-1312 (1989).
Aggarwal, S.K. et al., “Effect of Cisplatin on the Plasma Membrane Phosphatase Activities in Ascites Sarcoma-180 Cells: A Cytochemical Study”,Journal of Histochemistry and Cytochemistry, 31:307-317 (1985).
Defize, L.H. et al., “Dissociation of cellular responses to epidermal growth factor using anti-receptor monoclonal antibodies”,The EMBO Journal, 5:1187-1192 (1986).
Zick, Y. et al., “The Role of Antireceptor Antibodies in Stimulating Phosphorylation of the Insulin Receptor”,Journal of Biological Chemistry, 259:4396-4400 (1984).
Yarden, J., “Agonistic antibodies stimulate the kinase encodes by the neu Protooncogene in living cells by the oncogenic mutant is constitutively active”,Proc. Natl. Acad. Sci. USA, 87:2569-2573 (1990).
Aboud-Pirak et al. “Efficacy o
Brandis John W.
Hancock Miriam E.C.
Mann Elaina
Mischak Ronald P.
Monahan John J.
Berlex Laboratories Inc.
Huff Sheela J.
Millen White Zelano & Branigan P.C.
LandOfFree
Use of ligand-mimicking agents and anti-neoplastic drugs in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of ligand-mimicking agents and anti-neoplastic drugs in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of ligand-mimicking agents and anti-neoplastic drugs in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3395875